Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • About
  • Communities & Collections
  • Advanced Search
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. National Heart and Lung Institute
  4. National Heart and Lung Institute
  5. Cyclooxygenases and the cardiovascular system
 
  • Details
Cyclooxygenases and the cardiovascular system
File(s)
Cyclooxygenases and the Cardiovascular System final accepted.pdf (1.12 MB)
Accepted version
Author(s)
Mitchell, Jane A
Kirkby, Nicholas S
Ahmetaj-Shala, Blerina
Armstrong, Paul
Crescente, Marilena
more
Type
Journal Article
Abstract
Cyclooxygenase (COX)-1 and COX-2 are centrally important enzymes within the cardiovascular system with a range of diverse, sometimes opposing, functions. Through the production of thromboxane, COX in platelets is a pro-thrombotic enzyme. By contrast, through the production of prostacyclin, COX in endothelial cells is antithrombotic and in the kidney regulates renal function and blood pressure. Drug inhibition of COX within the cardiovascular system is important for both therapeutic intervention with low dose aspirin and for the manifestation of side effects caused by nonsteroidal anti-inflammatory drugs. This review focuses on the role that COX enzymes and drugs that act on COX pathways have within the cardiovascular system and provides an in-depth resource covering COX biology and pharmacology. The review goes on to consider the role of COX in both discrete cardiovascular locations and in associated organs that contribute to cardiovascular health. We discuss the importance of, and strategies to manipulate, the thromboxane: prostacyclin balance. Finally within this review the authors discuss testable COX-2-hypotheses intended to stimulate debate and facilitate future research and therapeutic opportunities within the field.
Date Issued
2021-01
Date Acceptance
2020-06-30
Citation
Pharmacology and Therapeutics, 2021, 217, pp.1-11
URI
http://hdl.handle.net/10044/1/81278
URL
https://www.sciencedirect.com/science/article/pii/S0163725820301546?via%3Dihub
DOI
https://www.dx.doi.org/10.1016/j.pharmthera.2020.107624
ISSN
0163-7258
Publisher
Elsevier
Start Page
1
End Page
11
Journal / Book Title
Pharmacology and Therapeutics
Volume
217
Copyright Statement
© 2020 Elsevier Inc. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
License URL
http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
British Heart Foundation
British Heart Foundation
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32640277
PII: S0163-7258(20)30154-6
Grant Number
RG/18/4/33541
FS/19/6/34129
Subjects
Aspirin
Celecoxib
Cyclooxygenase
Fish oil
Heart attack
Ibuprofen
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-07-05
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback